Impact of dosing on functional and clinical outcomes of patients with progressive pulmonary fibrosis treated with Nintedanib: data from a real-world, multicentric, Italian study Jacopo Cefalo; Francesco Varone; Fabrizio Luppi; Paolo Cameli; Stefania Cerri; Mariangela Valentina Puci; Alessia Martini; Giovanni Franco; Umberto Zanini; Tommaso Pianigiani; Athina Patsoura; Luca Richeldi; Elena Bargagli; Giovanni Sotgiu; Michele Mondoni;

Benefits of a Homecare Integral Patient Support Program in Idiopathic Pulmonary Fibrosis L. Cobo Sanchez; C. Ruiz Herrero; I. Cobos; J. Bespin; C. Gadea; P. Cerdá-Cortés; J. Palma; V. Vicens-Zygmunt; G. Bermudo; K. Portillo; A. Boldova; A. Robles; J. Arribas; J.A. Figuerola; R. Blavia; A. Moreno; D. Castillo; A. Villar; Y. Belmonte; D. Badenes-Bonet; D. Zayas; G. Suarez-Cuartin; L. Garcia-Bellmunt; J. Sellarés; S. Barril; J. Sans; M. Serra; D. Perich; L.L. Esteban; L. Esteban; E. Balcells; F. Gil; E. Ruiz; C. Fina; Maria Molina-Molina;

Expression Profiles of Nintedanib-Targeting Molecules in Progressive Pulmonary Fibrosis and Idiopathic Pulmonary Fibrosis Xin Zhang; Chengxin Liu; Yufen She; Xiaomin Fu; Xia Tong; Lanlan Zhang;